Company has said publicly numerous times that data from their two phase 3 studies will be published in Q1 2013 (with an ARX-04 right behind these two). Given that their drug trial (ARX 01) already had very favorable phase 3 data which was data on Sufentanil "head to head" study vs. morphine, it seems likely that their three additional product candidates in clinical development (which is measuring Sufentanil ONLY against a placebo!!!!) - it should look very good by comparison:
All 3 phase 3 studies are based on sufentanil:
ARX-02 for the treatment of cancer breakthrough pain;
ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and
ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.
Plus the recent buyers of the capital raise are locked up for 90 days, and cant sell their shares on good news. The pre-cap raise shareholder base is made up of 70% insiders, who are not selling. So given big short interest, its likely we could see a very nice squeeze, if data is good...